An anti-Alzheimer's nasal spray that could delay the progress of the disease by years has been developed by scientists at ...

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

The FDA added a warning to the label of esketamine nasal spray (Spravato), noting that long-term cognitive and memory ...

When Dr. Husseini Manji was developing the first-in-class depression medication Spravato at Johnson & Johnson he encountered plenty of naysayers.

Research from the College of Medicine provides promising insights into delaying the progression of Alzheimer’s disease for ...

Researchers at Texas A&M University have developed a nasal spray shown to delay disease progression in animals -- fueling ...

"This data gives patients the option to benefit from esketamine treatment either with or without an antidepressant," said ...

Corstasis to present pivotal trial data on Bumetanide Nasal Spray at AHA 2024, highlighting safety, and efficacy. #AHA2024. Home is where the heart is ...

Researchers have developed a promising nasal spray therapy targeting neuroinflammation in Alzheimer’s disease, potentially ...

COLLEGE STATION, Texas — November is National Alzheimer's Awareness Month and now a new therapy out of Texas A&M University could treat Alzheimer's disease through a nasal spray. Seven million ...